The current financial score of Avidity Biosciences Inc is 8.52. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 3.00M, representing a year-over-year decrease of 21.91%, while its net profit experienced a year-over-year decrease of 87.17%.
The current valuation score of Avidity Biosciences Inc is 7.60. Its current P/E ratio is -3.58, which is -54.60% below the recent high of -1.63 and -448.98% above the recent low of -19.66.
The current earnings forecast score of Avidity Biosciences Inc is 8.50. The average price target is 25.00, with a high of 25.00 and a low of 25.00.
The current price momentum score of Avidity Biosciences Inc is 4.82. Currently, the stock price is trading between the resistance level at 13.34 and the support level at 8.71, making it suitable for range-bound swing trading.
The current institutional shareholding score of Avidity Biosciences Inc is 3.00. The latest institutional shareholding proportion is 29.04%, representing a quarter-over-quarter decrease of 70.62%.
The current risk assessment score of Avidity Biosciences Inc is 3.78. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.